SynthesisWorld journal of surgical oncology2023
Prognostic value of consolidation-to-tumor ratio on computed tomography in NSCLC: a meta-analysis.
Synthesis in World journal of surgical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.
- Application of three-dimensional technology in video-assisted thoracoscopic surgery sublobectomy.Frontiers in oncology · 2024Pooled it
- Deep learning-based computed tomography quantification integrated with circulating tumor cells for prognostic evaluation in stage I lung adenocarcinoma.Quantitative imaging in medicine and surgery · 2026Article
- Spatial classification of clinical T1a-bN0 non-small cell lung cancer in superior segment based on three-dimensional reconstruction: optimizing surgical margin and operative strategy.Journal of thoracic disease · 2026Article
- Current real-life survival after segmentectomy for lung cancer.Frontiers in surgery · 2026Article
- MetaPredictomics: A Comprehensive Approach to Predict Postsurgical Non-Small Cell Lung Cancer Recurrence Using Clinicopathologic, Radiomics, and Organomics Data.Clinical nuclear medicine · 2025Article
- Radiomics models for predicting occult nodal metastasis in stage cT1a-bN0M0 lung adenocarcinoma: a multicenter study.Quantitative imaging in medicine and surgery · 2025Article
- Identification of the optimal threshold for predicting the infiltration degree of T1-stage lung adenocarcinoma using solid component volume and three-dimensional consolidation-to-tumor ratio in threshold segmentation.Quantitative imaging in medicine and surgery · 2025Article
- Prediction of STAS in lung adenocarcinoma with nodules ≤ 2 cm using machine learning: a multicenter retrospective study.BMC cancer · 2025Article
- Anatomic and clinical implications of venous drainage variations in superior segment resections for clinical T1N0 non-small cell lung cancer.Translational lung cancer research · 2024Article
- Advances in early detection of non-small cell lung cancer: A comprehensive review.Cancer medicine · 2024Review
- A combination of radiomic features, clinic characteristics, and serum tumor biomarkers to predict the possibility of the micropapillary/solid component of lung adenocarcinoma.Therapeutic advances in respiratory diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough several studies have confirmed the prognostic value of the consolidation to tumor ratio (CTR) in non-small cell lung cancer (NSCLC), there still remains controversial about it.
methodsWe systematically searched the PubMed, Embase, and Web of Science databases from inception to April, 2022 for eligible studies that reported the correlation between CTR and prognosis in NSCLC. Hazard ratios (HRs) with 95% confidence intervals (95% CIs) were extracted and pooled to assess the overall effects. Heterogeneity was estimated by I
resultsA total of 29 studies published between 2001 and 2022 with 10,347 patients were enrolled. The pooled results demonstrated that elevated CTR was associated with poorer overall survival (HR = 1.88, 95% CI 1.42-2.50, P < 0.01) and disease-free survival (DFS)/recurrence-free survival (RFS)/progression-free survival (PFS) (HR = 1.42, 95% CI 1.27-1.59, P < 0.01) in NSCLC. According to subgroup analysis by the cut-off value of CTR and histology type, both lung adenocarcinoma and NSCLC patients who had a higher CTR showed worse survival. Subgroup analysis stratified by country revealed that CTR was a prognostic factor for OS and DFS/RFS/PFS in Chinese, Japanese, and Turkish patients.
conclusionsIn NSCLC patients with high CTR, the prognosis was worse than that with low CTR, indicating that CTR may be a prognostic factor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.